Earnings call: Amarin reports Q3 revenue dip amid U.S. generic competition By Investing.com
Amarin Corporation (NASDAQ:), a biopharmaceutical company, has reported a decline in its third-quarter revenue for the year 2024, primarily due to increased competition from generic… Read More »Earnings call: Amarin reports Q3 revenue dip amid U.S. generic competition By Investing.com










